Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q2 2025 Earnings Presentation
23 slides from Adc Therapeutics Sa's earnings presentation, Aug 12, 2025
Slide 1: 2Q 2025 Earnings Call
2Q 2025 Earnings Call August 12, 2025
Slide 2: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Introduction Mohamed Zaki 02 Chief Medical Officer Clinical Highlights Pepe Carmona Financial Update 03 Chief Financial Officer 04 Q&A 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Key Business Updates
Key Business Updates Commercial § 2Q 2025 net product revenues of $18.1 million as compared to $17.0 million in same quarter 2024 Performance § Total 1H net product revenue was $35.5 million compared to $34.9 million during the 1H of 2024 § LOTIS-7 data presented at EHA2025 and ICML • ZYNLONTA in co
Slide 5: Advancing ZYNLONTA Development Into 2L+ B-Cell Lymphomas
Advancing ZYNLONTA Development Into 2L+ B-Cell Lymphomas Potential To Move Into 2L+ DLBCL Overall Response Rate Complete Response Rate DLBCL FL MZL LOTIS-5 ZYNLONTA + rituximab1 (N=20) ~80% ~50% 1L LOTIS-7 ZYNLONTA + glofitamab2 ~93% ~87% (N=30) LOTIS-5 2L+ Potential Benefit In Indolent Lymphomas LO
Slide 6: ZYNLONTA U.S. Peak Revenue Potential of $600M-1B
ZYNLONTA U.S. Peak Revenue Potential of $600M-1B ZYNLONTA $600M-1B Peak Revenue in DLBCL & Indolent Lymphomas 2L+ ZYNLONTA plus bispecific LOTIS-7 $500M-800M 2L+ Indolent 2L+ ZYNLONTA plus rituximab lymphomas $200M-300M* $100M-200M LOTIS-5 CURRENT INDICATION 3L+ Monotherapy Peak revenue projection a
Slide 7: Two Distinct Segments in r/r DLBCL Treatment Options
Two Distinct Segments in r/r DLBCL Treatment Options Current r/r DLBCL U.S. Market 2L+ treatment choice based on efficacy, safety and accessibility in context of 2L Complex therapies Broadly accessible therapies ~75% individual patient need ~12k patients ~25% ~20% CAR T ADCs, mAbs, Chemo / other ~5%
Slide 8: ZYNLONTA Combinations Potentially Raising the Bar on Efficacy in r/r DLBCL
ZYNLONTA Combinations Potentially Raising the Bar on Efficacy in r/r DLBCL 87% CR Complex LOTIS-7 (ZYNLONTA + glofitamab) Opportunity Therapies → We believe LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies → Leading CR rate that
Slide 9: LOTIS-5: Confirmatory Trial of ZYNLONTA in Combination with Rituximab in 2L+ DLBCL
LOTIS-5: Phase 3 Confirmatory Trial of ZYNLONTA in Combination with Rituximab in 2L+ DLBCL Treatment Period Follow-Up Period Lonca (0.15 mg/kg) + rituximab (375 mg/m2) Loncastuximab tesirine Nonrandomized Q3W for 2 cycles For both parts of the study, End of Treatment Safety Run-in 0.15 mg/kg + ritux
Slide 10: LOTIS-7 Combination Rationale and Biological Hypothesis
LOTIS-7 Combination Rationale and Biological Hypothesis Potent, single agent drugs with distinct and complementary MOAs ZYNLONTA GLOFITAMAB ANTI-CD19 ADC ANTI-CD20/CD3 T-Cell engaging bispecific antibody EFFICACY SAFETY § Expected to have additive § No overlapping non-hematologic toxicities expected
Slide 11: LOTIS-7: Phase 1b Trial of ZYNLONTA in Combination with Glofitamab
LOTIS-7: Phase 1b Trial of ZYNLONTA in Combination with Glofitamab SCREENING PERIOD TREATMENT PERIOD Study Population (≤28 DAYS) (CYCLES OF 21 DAYS) → Relapsed or Refractory B-NHL patients, ECOG PS 0 – 2, and have received: Escalating doses of Part 1 ZYNLONTA IV + glofitamab IV Q3W1 – Part 1: >2 sys
Slide 12: LOTIS-7 Phase 1b Trial: Baseline Patient Characteristics
CORPORATE LOTIS-7 Phase 1b Trial: Baseline Patient Characteristics r/r Large B-Cell Lymphoma Treated Population (N=41) as of data cutoff of April 14, 2025 All patients enrolled in US & Europe with majority in US 120 µg/kg 150 µg/kg N=41 120 µg/kg 150 µg/kg N=20 N=21 N=41 N=20 N=21 IPI Score Median a
Slide 13: LOTIS-7 Phase 1b Trial: Safety Summary
CORPORATE LOTIS-7 Phase 1b Trial: Safety Summary r/r Large B-Cell Lymphoma Treated Population (N=41) as of data cutoff of April 14, 2025 120 µg/kg 150 µg/kg All n=20 n=21 n = 41 Grade 3/4 TEAEs (> 5% of patients)a 11 (55%) 12 (57.1%) 23 (56.1%) Neutropenia 4 (20%) 6 (28.6%) 10 (24.4%) Anemia 1 (5%)
Slide 14: LOTIS-7 Phase 1b Trial: Safety Summary
CORPORATE LOTIS-7 Phase 1b Trial: Safety Summary r/r Large B-Cell Lymphoma Treated Population (N=41) as of data cutoff of April 14, 2025 120 µg/kg 150 µg/kg All Patients with TEAEs leading to study drug discontinuationa n=20 n=21 n = 41 TEAE leading to loncastuximab discontinuation only 1 (5%) 2 (9.
Slide 15: LOTIS-7 Phase 1b Trial: CRS/ICANS Profile & Management
CORPORATE LOTIS-7 Phase 1b Trial: CRS/ICANS Profile & Management r/r Large B-Cell Lymphoma Treated Population (N=41) as of data cutoff of April 14, 2025 120 µg/kg 150 µg/kg All n=20 n=21 n = 41 Cytokine Release Syndromea Any grade 11 (55%) 5 (23.8%) 16 (39.0%) • Grade 1 and 2 CRS cases managed with
Slide 16: LOTIS-7 Phase 1b Trial: Overall Response Rate (ORR)
LOTIS-7 Phase 1b Trial: Overall Response Rate (ORR) r/r Large B-Cell Lymphoma Efficacy Evaluable Population (N=30) as of April 14, 2025 120 µg/kg 150 µg/kg Total n=15 % n=15 % n=30 % ORR (CR + PR) 14 93.3% 14 93.3% 28 93.3% Complete Response (CR) 13 86.7% 13 86.7% 26 86.7% Partial Response (PR) 1 6.
Slide 17: LOTIS-7 Phase 1b Trial: Efficacy Over Time
LOTIS-7 Phase 1b Trial: Efficacy Over Time r/r Large B-Cell Lymphoma Treated Population (N=41) as of April 14, 2025 → → → 1 (120 ug/kg) 184-705* → → 2 164-704 → → 3 404-703 → → 4 → 335-702 → → 5 121-706 → 6 Ø Most responses observed at initial assessment → Glofit + Lonca 120 µg/kg 383-704 → →→ 7 121
Slide 18: 2Q 2025 Selected Financial Data
2Q 2025 Selected Financial Data Balance Sheet June 30, 2025 Cash and cash equivalents ($M) 264.6* Statement of Operations 2Q 2025 ($M) 2Q 2024 ($M) YoY % Product Revenues, Net 18.1 17.0 6.2 Total Revenue 18.8 17.4 8.2 Restructuring & Impairment** 13.1 - 100.0 Total Operating Expenses 63.0 46.5 35.6
Slide 19: Delivering On Our Strategy
Delivering On Our Strategy Upcoming Expected Milestones 2H2025 1H2026 2H2026 1H2027 Share fuller/more Full enrollment 100 pts in Publication and potential LOTIS-7 ZYNLONTA mature data recommended dose compendia LOTIS-7 Engage regulatory agencies, evaluate compendia strategies Reach prespecified numb
Slide 20: Thank You
Thank You ® THERAPEUTICS Innovating Science. Inspiring Hope.
Slide 21: ZYNLONTA Has Potential to Disrupt r/r DLBCL Market and Unlock Significant Growth
ZYNLONTA Has Potential to Disrupt r/r DLBCL Market and Unlock Significant Growth Opportunity in Both Segments Complex therapies Broadly accessible therapies (CAR T-cell therapy, Bispecifics) (ADCs, mAbs, Chemo / other) 100 - 50 - Complete Response Rate (%) Complete Response Rate (%) 50% LOTIS-5 (Lon
Slide 22: ZYNLONTA Phase 2 IIT Data Showed 69.2% CR Rate in r/r MZL
ZYNLONTA Phase 2 IIT Data Showed 69.2% CR Rate in r/r MZL r/r MZL Patient Population University of Miami phase 2 IIT in r/r MZL* → Estimated 3–4k 2L+ MZL → Highlights of ICML 2025 abstract by Dr. Izidore Lossos on study of ZYNLONTA patients are drug-treated in in patients with r/r MZL: the US annual
Slide 23: ZYNLONTA + Rituximab Phase IIT Data Show 77% CR Rate in r/r FL
ZYNLONTA + Rituximab Phase 2 IIT Data Show 77% CR Rate in r/r FL 2L+ FL Patient Population University of Miami phase 2 IIT in 2L+ FL ASH 2024 → Estimated 6k 2L+ FL patients are presentation & Lancet Haem publication highlights11 drug-treated in the US annually1, of which ~20% relapse within the firs